Advanced search
Publication Cover
Emerging Microbes & Infections Volume 13, 2024 - Issue 1
Submit an article Journal homepage
1,616
Views
0
CrossRef citations to date
0
Altmetric
Emerging and Re-Emerging Coronaviruses

Effectiveness of a broad-spectrum bivalent mRNA vaccine against SARS-CoV-2 variants in preclinical studies

Jing Lua State Key Laboratory of Genetic Engineering, School of Life Sciences, Zhongshan Hospital, Fudan University, Shanghai, People’s Republic of China;b Shanghai Institute of Infectious Disease and Biosecurity, Fudan University, Shanghai, People’s Republic of China;c Center for mRNA Translational Research, Fudan University, Shanghai, People’s Republic of China;d Shanghai RNACure Biopharma Co., Ltd, Shanghai, People’s Republic of ChinaCorrespondence[email protected]
View further author information
,
Shudan Tana State Key Laboratory of Genetic Engineering, School of Life Sciences, Zhongshan Hospital, Fudan University, Shanghai, People’s Republic of China;b Shanghai Institute of Infectious Disease and Biosecurity, Fudan University, Shanghai, People’s Republic of China;c Center for mRNA Translational Research, Fudan University, Shanghai, People’s Republic of China;d Shanghai RNACure Biopharma Co., Ltd, Shanghai, People’s Republic of ChinaView further author information
,
Hao Gud Shanghai RNACure Biopharma Co., Ltd, Shanghai, People’s Republic of ChinaView further author information
,
Kunpeng Liue State Key Laboratory of Virology, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, People’s Republic of China;f University of the Chinese Academy of Sciences, Beijing, People’s Republic of ChinaView further author information
,
Wei Huangd Shanghai RNACure Biopharma Co., Ltd, Shanghai, People’s Republic of ChinaView further author information
,
Zhaoli Yud Shanghai RNACure Biopharma Co., Ltd, Shanghai, People’s Republic of ChinaView further author information
,
Guoliang Lua State Key Laboratory of Genetic Engineering, School of Life Sciences, Zhongshan Hospital, Fudan University, Shanghai, People’s Republic of China;b Shanghai Institute of Infectious Disease and Biosecurity, Fudan University, Shanghai, People’s Republic of China;c Center for mRNA Translational Research, Fudan University, Shanghai, People’s Republic of ChinaView further author information
,
Zihan Wua State Key Laboratory of Genetic Engineering, School of Life Sciences, Zhongshan Hospital, Fudan University, Shanghai, People’s Republic of China;b Shanghai Institute of Infectious Disease and Biosecurity, Fudan University, Shanghai, People’s Republic of China;c Center for mRNA Translational Research, Fudan University, Shanghai, People’s Republic of ChinaView further author information
,
Xiaobo Gaod Shanghai RNACure Biopharma Co., Ltd, Shanghai, People’s Republic of ChinaView further author information
,
Jinghua Zhaoa State Key Laboratory of Genetic Engineering, School of Life Sciences, Zhongshan Hospital, Fudan University, Shanghai, People’s Republic of China;b Shanghai Institute of Infectious Disease and Biosecurity, Fudan University, Shanghai, People’s Republic of China;c Center for mRNA Translational Research, Fudan University, Shanghai, People’s Republic of China;d Shanghai RNACure Biopharma Co., Ltd, Shanghai, People’s Republic of ChinaView further author information
,
Zongting Yaod Shanghai RNACure Biopharma Co., Ltd, Shanghai, People’s Republic of ChinaView further author information
,
Feng Yid Shanghai RNACure Biopharma Co., Ltd, Shanghai, People’s Republic of ChinaView further author information
,
Yantao Yangd Shanghai RNACure Biopharma Co., Ltd, Shanghai, People’s Republic of ChinaView further author information
,
Hu Wangd Shanghai RNACure Biopharma Co., Ltd, Shanghai, People’s Republic of ChinaView further author information
,
Xue Hud Shanghai RNACure Biopharma Co., Ltd, Shanghai, People’s Republic of ChinaView further author information
,
Mingqing Lue State Key Laboratory of Virology, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, People’s Republic of China;f University of the Chinese Academy of Sciences, Beijing, People’s Republic of ChinaView further author information
,
Wei Lia State Key Laboratory of Genetic Engineering, School of Life Sciences, Zhongshan Hospital, Fudan University, Shanghai, People’s Republic of China;b Shanghai Institute of Infectious Disease and Biosecurity, Fudan University, Shanghai, People’s Republic of China;c Center for mRNA Translational Research, Fudan University, Shanghai, People’s Republic of ChinaView further author information
,
Hui Zhoud Shanghai RNACure Biopharma Co., Ltd, Shanghai, People’s Republic of ChinaView further author information
,
Hang Yud Shanghai RNACure Biopharma Co., Ltd, Shanghai, People’s Republic of ChinaView further author information
,
Chao Shane State Key Laboratory of Virology, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, People’s Republic of China;f University of the Chinese Academy of Sciences, Beijing, People’s Republic of China;g Hubei Jiangxia Laboratory, Wuhan, People’s Republic of ChinaCorrespondence[email protected]
View further author information
&
Jinzhong Lina State Key Laboratory of Genetic Engineering, School of Life Sciences, Zhongshan Hospital, Fudan University, Shanghai, People’s Republic of China;b Shanghai Institute of Infectious Disease and Biosecurity, Fudan University, Shanghai, People’s Republic of China;c Center for mRNA Translational Research, Fudan University, Shanghai, People’s Republic of ChinaCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0001-5666-8526View further author information
ORCID Icon show all
Article: 2321994 | Received 07 Nov 2023, Accepted 16 Feb 2024, Published online: 29 Feb 2024

References

  • Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. N Engl J Med. 2020;383(27):2603–2615. doi:10.1056/NEJMoa2034577
  • Baden LR, El Sahly HM, Essink B, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021;384(5):403–416. doi:10.1056/NEJMoa2035389
  • Faria NR, Mellan TA, Whittaker C, et al. Genomics and epidemiology of the P.1 SARS-CoV-2 lineage in Manaus, Brazil. Science. 2021;372(6544):815–821.
  • Planas D, Veyer D, Baidaliuk A, et al. Reduced sensitivity of SARS-CoV-2 variant delta to antibody neutralization. Nature. 2021;596(7871):276–280. doi:10.1038/s41586-021-03777-9
  • Tegally H, Wilkinson E, Giovanetti M, et al. Detection of a SARS-CoV-2 variant of concern in South Africa. Nature. 2021;592(7854):438–443. doi:10.1038/s41586-021-03402-9
  • Volz E, Mishra S, Chand M, et al. Assessing transmissibility of SARS-CoV-2 lineage B.1.1.7 in England. Nature. 2021;593(7858):266–269. doi:10.1038/s41586-021-03470-x
  • Collie S, Champion J, Moultrie H, et al. Effectiveness of BNT162b2 vaccine against Omicron variant in South Africa. N Engl J Med. 2022;386(5):494–496. doi:10.1056/NEJMc2119270
  • Islam MR, Shahriar M, Bhuiyan MA. The latest Omicron BA.4 and BA.5 lineages are frowning toward COVID-19 preventive measures: A threat to global public health. Health Sci Rep. 2022;5(6):e884. doi:10.1002/hsr2.884
  • Lu L, Mok BWY, Chen LL, et al. Neutralization of severe acute respiratory syndrome coronavirus 2 omicron variant by sera from BNT162b2 or CoronaVac vaccine recipients. Clin Infect Dis. 2022;75(1):e822–e826. doi:10.1093/cid/ciab1041
  • Cele S, Jackson L, Khoury DS, et al. Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization. Nature. 2022;602(7898):654–656. doi:10.1038/s41586-021-04387-1
  • Dejnirattisai W, Huo J, Zhou D, et al. SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses. Cell. 2022;185(3):467–484.e15. doi:10.1016/j.cell.2021.12.046
  • Liu L, Iketani S, Guo Y, et al. Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2. Nature. 2022;602(7898):676–681. doi:10.1038/s41586-021-04388-0
  • Wang Q, Bowen A, Valdez R, et al. Antibody response to omicron BA.4-BA.5 bivalent booster. N Engl J Med. 2023;388(6):567–569. doi:10.1056/NEJMc2213907
  • Collier AY, Miller J, Hachmann NP, et al. Immunogenicity of BA.5 bivalent mRNA vaccine boosters. N Engl J Med. 2023;388(6):565–567. doi:10.1056/NEJMc2213948
  • Lu J, Lu G, Tan S, et al. A COVID-19 mRNA vaccine encoding SARS-CoV-2 virus-like particles induces a strong antiviral-like immune response in mice. Cell Res. 2020;30(10):936–939. doi:10.1038/s41422-020-00392-7
  • Tan S, Hu X, Li Y, et al. Preclinical evaluation of RQ3013, a broad-spectrum mRNA vaccine against SARS-CoV-2 variants. Sci Bull (Beijing). 2023;68(2):3192–3206. doi:10.1016/j.scib.2023.11.024
  • Walsh EE, Frenck RW, Falsey J, et al. Safety and immunogenicity of Two RNA-based COVID-19 vaccine candidates. N Engl J Med. 2020;383(25):2439–2450. doi:10.1056/NEJMoa2027906
  • Corbett KS, Edwards DK, Leist SR, et al. SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness. Nature. 2020;586(7830):567–571. doi:10.1038/s41586-020-2622-0
  • Ebenig A, Muraleedharan S, Kazmierski J, et al. Vaccine-associated enhanced respiratory pathology in COVID-19 hamsters after TH2-biased immunization. Cell Rep. 2022;40(7):111214. doi:10.1016/j.celrep.2022.111214
  • McCray PB Jr., Pewe L, Wohlford-Lenane C, et al. Lethal infection of K18-hACE2 mice infected with severe acute respiratory syndrome coronavirus. J Virol. 2007;81(2):813–821. doi:10.1128/JVI.02012-06
  • Radvak P, Kwon HJ, Kosikova M, et al. SARS-CoV-2 B.1.1.7 (alpha) and B.1.351 (beta) variants induce pathogenic patterns in K18-hACE2 transgenic mice distinct from early strains. Nat Commun. 2021;12(1):6559. doi:10.1038/s41467-021-26803-w
  • Winkler ES, Bailey AL, Kafai NM, et al. SARS-CoV-2 infection of human ACE2-transgenic mice causes severe lung inflammation and impaired function. Nat Immunol. 2020;21(11):1327–1335. doi:10.1038/s41590-020-0778-2
  • Munoz-Fontela C, Dowling WE, Funnell SGP, et al. Animal models for COVID-19. Nature. 2020;586(7830):509–515. doi:10.1038/s41586-020-2787-6
  • Cavagnaro JA. Preclinical safety evaluation of biotechnology-derived pharmaceuticals. Nat Rev Drug Discov. 2002;1(6):469–475. doi:10.1038/nrd822
  • Thompson MG, Burgess JL, Naleway AL, et al. Prevention and attenuation of COVID-19 with the BNT162b2 and mRNA-1273 Vaccines. N Engl J Med. 2021;385(4):320–329. doi:10.1056/NEJMoa2107058
  • Markov PV, Ghafari M, Beer M, et al. The evolution of SARS-CoV-2. Nat Rev Microbiol. 2023;21(6):361–379. doi:10.1038/s41579-023-00878-2
  • Zhao Y, Ni W, Liang S, et al. Vaccination with Span, an antigen guided by SARS-CoV-2 S protein evolution, protects against challenge with viral variants in mice. Sci Transl Med. 2023;15(677):eabo3332. doi:10.1126/scitranslmed.abo3332
  • Offit PA. Bivalent COVID-19 vaccines — A cautionary tale. N Engl J Med. 2023;388(6):481–483. doi:10.1056/NEJMp2215780
  • Cai J, Deng X, Yang J, et al. Modeling transmission of SARS-CoV-2 Omicron in China. Nat Med. 2022;28(7):1468–1475. doi:10.1038/s41591-022-01855-7
  • McBride DS, Garushyants SK, Franks J, et al. Accelerated evolution of SARS-CoV-2 in free-ranging white-tailed deer. Nat Commun. 2023;14(1):5105. doi:10.1038/s41467-023-40706-y

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.